EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Safety and Efficacy of Nerinetide at Year 1 in Participants Enrolled in ESCAPE‐NEXT: A Multicenter, Double‐Blind, Randomized Controlled Trial

Corey Adams iD, Kathy Heard iD, Yatika Kohli, Shabnam Vatanpour iD, Jorg Berrouschot iD, Brian Buck iD, Andrew Demchuk iD, Diederik Dippel iD, Franziska Dorn iD, Thalia Field iD, Mario Muto, Mirko Pham iD und 8 weitere

Journal of the American Heart Association · 07.07.2026 · 15 (13)

DOI: 10.1161/jaha.125.044080 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 07.07.2026. Verfasst von Corey Adams und 19 weiteren Autor:innen. Beteiligte Einrichtung: NoNO Inc. Toronto ON Canada. Hauptthemen laut MEDLINE: Neuroprotective Agents, Ischemic Stroke, Stroke. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nerinetide is a neuroprotective agent recently evaluated in the ESCAPE‐NEXT (Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis) trial (NCT04462536), which was terminated after failing to meet its Day 90 primary end point; however, by that time, Year 1 follow‐up outcomes were already available for 513 participants.

Methods

The primary end point at Year 1 was functional independence, defined as modified Rankin Scale score 0 to 2, analyzed by logistic regression adjusted for treatment and baseline covariates. In a post hoc analysis, the interaction between early (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroprotective AgentsIschemic StrokeStrokeHumansDouble-Blind MethodFemaleMaleTime FactorsAgedTreatment OutcomeMiddle AgedPeptide Fragments

Stichwörter der Autor:innen

PSD‐95 inhibitoracute ischemic strokenerinetideneuroprotectionrandomized controlled trial

Substanzen

Neuroprotective AgentsnerinetidePeptide Fragments

Autor:innen und Institutionen

  • NoNO Inc. Toronto ON Canada.
  • Cumming School of Medicine University of Calgary AB Canada.
  • Klinikum Altenburger Land, Neurology Altenburg Germany.
  • University of Alberta Hospital Edmonton AB Canada.
  • Erasmus MC University Medical Center Rotterdam Netherlands.
  • Faculty of Medicine University of Bonn Germany.

ORCID-Profile: Corey Adams, Kathy Heard, Shabnam Vatanpour, Jorg Berrouschot, Brian Buck, Andrew Demchuk, Diederik Dippel, Franziska Dorn, Thalia Field, Mirko Pham, Richard H Swartz, Brian A van Adel, Bijoy Menon, Mayank Goyal, Michael D Hill, Michael Tymianski

Zitieren

APA

Adams, C., Heard, K., Kohli, Y., Vatanpour, S., Berrouschot, J., Buck, B., Demchuk, A., Dippel, D., Dorn, F., Field, T., Muto, M., Pham, M., Ryckborst, K. J., Swartz, R. H., van Adel, B. A., Menon, B., Goyal, M., Hill, M. D., Tymianski, M., & ESCAPE‐NEXT Investigators (2026). Safety and Efficacy of Nerinetide at Year 1 in Participants Enrolled in ESCAPE‐NEXT: A Multicenter, Double‐Blind, Randomized Controlled Trial. Journal of the American Heart Association, 15(13). https://doi.org/10.1161/jaha.125.044080

Vancouver

Adams C, Heard K, Kohli Y, Vatanpour S, Berrouschot J, Buck B, et al. Safety and Efficacy of Nerinetide at Year 1 in Participants Enrolled in ESCAPE‐NEXT: A Multicenter, Double‐Blind, Randomized Controlled Trial. Journal of the American Heart Association. 2026;15(13). doi:10.1161/jaha.125.044080

BibTeX
@article{Adams2026,
  author = {Adams, Corey and Heard, Kathy and Kohli, Yatika and Vatanpour, Shabnam and Berrouschot, Jorg and Buck, Brian and Demchuk, Andrew and Dippel, Diederik and Dorn, Franziska and Field, Thalia and Muto, Mario and Pham, Mirko and Ryckborst, Karla J and Swartz, Richard H and van Adel, Brian A and Menon, Bijoy and Goyal, Mayank and Hill, Michael D and Tymianski, Michael and ESCAPE‐NEXT Investigators, ESCAPE‐NEXT Investigators},
  title = {Safety and Efficacy of Nerinetide at Year 1 in Participants Enrolled in ESCAPE‐NEXT: A Multicenter, Double‐Blind, Randomized Controlled Trial},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {13},
  doi = {10.1161/jaha.125.044080}
}
Kostenlos starten →